GSK plans to become leading supplier of anti-HIV drugs for state needs in Russia
UK pharma major GlaxoSmithKline (LSE: GSK) plans to become a leading supplier of anti-HIV drugs for state needs in Russia, according to sources in the Russian Ministry of Health, reports The Pharma Letter’s local correspondent.
To date, the company has secured several contracts with the Russian government for the supplies of anti-HIV and other drugs totaling more than 1.5 billion roubles ($24 million) for the current year. The company decided to not use services of distributors and directly sign contracts with the federal Ministry of Health.
GSK confirmed the decision to independently participate in deliveries of anti-HIV drugs to the Russian government, by saying that “it will lead to ensuring the stability of supplies and will contribute to the most optimal planning."
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Pharmaceutical
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze